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Endomyocardial biopsy is the standard method of monitoring for rejection in recipients of a cardiac transplant. However, this procedure is uncomfortable, and there are
risks associated with it. Gene-expression profiling of peripheral-blood specimens has
been shown to correlate with the results of an endomyocardial biopsy.
Methods

We randomly assigned 602 patients who had undergone cardiac transplantation
6 months to 5 years previously to be monitored for rejection with the use of geneexpression profiling or with the use of routine endomyocardial biopsies, in addition
to clinical and echocardiographic assessment of graft function. We performed a
noninferiority comparison of the two approaches with respect to the composite
primary outcome of rejection with hemodynamic compromise, graft dysfunction
due to other causes, death, or retransplantation.
Results

During a median follow-up period of 19 months, patients who were monitored with
gene-expression profiling and those who underwent routine biopsies had similar
2-year cumulative rates of the composite primary outcome (14.5% and 15.3%, respectively; hazard ratio with gene-expression profiling, 1.04; 95% confidence interval, 0.67 to 1.68). The 2-year rates of death from any cause were also similar in the
two groups (6.3% and 5.5%, respectively; P = 0.82). Patients who were monitored
with the use of gene-expression profiling underwent fewer biopsies per person-year
of follow-up than did patients who were monitored with the use of endomyocardial
biopsies (0.5 vs. 3.0, P<0.001).
Conclusions

Among selected patients who had received a cardiac transplant more than 6 months
previously and who were at a low risk for rejection, a strategy of monitoring for
rejection that involved gene-expression profiling, as compared with routine biopsies, was not associated with an increased risk of serious adverse outcomes and resulted in the performance of significantly fewer biopsies. (ClinicalTrials.gov number, NCT00351559.)
n engl j med 362;20
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A

dvances in immunosuppression after cardiac transplantation have increased
the rates of 1-year survival among recipients to nearly 90%. However, acute cellular rejection is still observed during the first year after
transplantation (at a rate of approximately 30 to
40%) and occurs at a lower rate thereafter.1-4 Rejection episodes are associated with an increased
risk of allograft vasculopathy and loss.5-7 Endomyocardial biopsy has remained the primary method
of monitoring for rejection, despite the discomfort
and the rare but potentially serious complications
of the procedure.8-12
Quantitative assessment of mononuclear-cell
gene expression in peripheral-blood specimens
has been explored as a method for detecting the
rejection of a cardiac transplant.13,14 This approach
has been investigated as an alternative to an endomyocardial biopsy13,14 and has led to the development and validation of a commercially available test that has been shown to correlate with
the results of an endomyocardial biopsy.14 Although this gene-expression test has been used
at some cardiac transplantation centers to monitor transplant recipients for rejection,15 it has not
been compared systematically in clinical practice
with the current standard approach to monitoring
for rejection with the use of routine biopsies.
We conducted the Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial to
test the hypothesis that a strategy of monitoring
for rejection that involves gene-expression profiling is not inferior to a strategy that involves
routine biopsies, with respect to a composite outcome of rejection with hemodynamic compromise,
graft dysfunction, death, or retransplantation.

Me thods
Study Design and Oversight

The IMAGE study was a randomized, event-driven, noninferiority trial conducted at 13 U.S. cardiac transplantation centers from January 2005
through October 2009. The study design has been
described previously,16 and additional details are
included in the Supplementary Appendix, available with the full text of this article at NEJM.org.
The trial was sponsored by XDx, in which Stanford University owns equity; XDx is the maker of
the AlloMap test. The academic investigators initiated and designed the study in collaboration
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with the sponsor. The trial protocol was approved
by the institutional review board at each participating center. The sponsor was involved in the
collection and source verification of the data,
and the sponsor’s biostatisticians performed the
analyses with oversight from the study steering
committee. The first author wrote the initial draft
of the manuscript, and revisions were made by
all the authors. Investigators at the core echocardiography laboratory at Stanford University reread all the echocardiograms to calculate the left
ventricular ejection fractions that were used in
the analyses. An independent end-points committee adjudicated all primary events. A data and
safety monitoring board monitored efficacy and
safety data. The academic investigators vouch for
the accuracy and completeness of the data and of
all analyses.
Patients

Patients 18 years of age or older who had undergone a cardiac transplantation between 1 and
5 years previously were eligible for enrollment.
Data on cardiac transplantations at participating
centers were obtained from the Organ Procurement and Transplantation Network of the United
Network of Organ Sharing (http://optn.transplant
.hrsa.gov). A protocol amendment on November
27, 2007, expanded enrollment to include patients
who had undergone a cardiac transplantation
more than 6 months previously, in order to facilitate enrollment. At the time of enrollment,
patients were required to be in a clinically stable
condition and to have a left ventricular ejection
fraction of 45% or greater. Exclusion criteria included a history of severe allograft vasculopathy,
antibody-mediated rejection, or the presence of
signs or symptoms of heart failure. All participating patients provided written informed consent.
Study Procedures

Patients were randomly assigned, in a 1:1 ratio, to
undergo monitoring for rejection by means of
gene-expression profiling (gene-profiling group) or
routine endomyocardial biopsies (biopsy group).
Randomization was stratified according to study
center and according to the interval since transplantation (1 year or less, 2 to 3 years, or 4 to
5 years). Monitoring for rejection with the use of
the assigned strategy was performed at prespecified intervals in both groups according to the
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protocols at the individual transplantation centers (see Table 2 in the Supplementary Appendix).
All patients in both groups were also monitored
with the use of clinical and echocardiographic
assessments. The performance of a biopsy was
mandated by the protocol for patients in both
groups if clinical or echocardiographic evidence
of graft dysfunction was present or, in the case of
the gene-profiling group, if the gene-expression
profiling score was above a specified threshold.
If patients had consistently elevated gene-expression profiling scores and no evidence of rejection
on at least two previous biopsies, the protocol did
not require further biopsies to be performed in
the case of a third or subsequent instance of a
score above the threshold.
Gene-expression testing was performed with
the use of the AlloMap test (XDx), which evaluates expression levels of 11 informative genes that
were shown in previous studies to distinguish between rejection and the absence of rejection. Possible scores range from 0 to 40, with higher scores
having a stronger correlation with histologic rejection. In a previous study, a score below 30 had
a negative predictive value of 99.6% for histologic evidence of rejection.14 Therefore, the initial
protocol for the current trial specified a score of
30 as a threshold for a mandatory biopsy. However, on November 7, 2005, the protocol was
amended to increase the threshold for a mandatory biopsy to a score of 34 in order to minimize
the number of biopsies that would be needed in
the gene-profiling group. Further details of the
test and of the characteristics of the test threshold are provided in the Supplementary Appendix.
Patients were followed for a maximum of 24
months, until they died, or until the study completion date, whichever occurred first. The study
ended in October 2009, after the minimum prespecified number of primary outcome events (54)
had occurred.
Outcomes

The primary outcome was the first occurrence of
rejection with hemodynamic compromise, graft
dysfunction due to other causes, death, or retransplantation. Definitions of each component of the
composite primary outcome are provided in the
Supplementary Appendix. Secondary outcomes included death from any cause, the number of biopsies performed, and biopsy-related complications. We also assessed the patients’ quality of
1892
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life and their satisfaction with the method of
monitoring for rejection. Quality of life was assessed with the use of the Medical Outcomes
Study 12-Item Short Form Health Survey (SF-12).
We assessed satisfaction by asking the patients,
“How satisfied are you with the current method
of detecting rejection?” Responses were scored
on an ordinal scale that ranged from 1 (very unhappy) to 10 (very happy).
Statistical Analysis

The trial was designed to test for the noninferiority of gene-expression profiling, as compared with
routine endomyocardial biopsies, with respect to
the primary outcome. The primary analysis, which
was conducted in the intention-to-treat population, was a comparison between the groups of the
time to the first occurrence of the composite primary outcome; the comparison was made with
the use of the hazard ratios calculated from a Cox
proportional-hazards model. The strategy of geneexpression profiling was considered to be noninferior to the strategy of routine biopsies if the
one-sided upper boundary of the 95% confidence
interval for the hazard ratio with the gene-expression–profiling strategy, as compared with the biopsy strategy, was less than the prespecified margin for noninferiority (2.054). This relative margin
was derived assuming a primary-event rate of 5%
per year in the biopsy group and the possibility of
an event rate of up to 10% per year in the geneprofiling group. This difference, in the view of the
investigators, would balance the expected benefit
with respect to patient convenience and satisfaction that would result from a reduction in the number of biopsies performed. The study required that
a minimum of 54 primary events occur, in order
to exclude the inferiority null hypothesis with 80%
power, assuming an overall event rate of 5% per
year, a rate that was estimated from published observational data.17,18
Means and standard deviations for continuous variables were calculated and compared with
the use of Student’s t-test. Numbers and proportions for categorical variables were compared with
the use of Fisher’s exact test. Both the Kaplan–
Meier method and Cox proportional-hazards models were used to estimate event rates. The effects
of an interaction between strategy group and center and between strategy group and interval between transplantation and randomization were
tested at an alpha level of 0.15.
nejm.org
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2946 Patients underwent cardiac
transplantation at a participating
center 6 mo–5 yr previously

1281 Were invited to participate

679 Were excluded
296 Declined to participate
275 Were excluded by investigator
108 Had unknown reasons

602 Underwent randomization

297 Were assigned to monitoring with
gene-expression profiling

305 Were assigned to monitoring with
routine biopsies

26 Were excluded
10 Did not undergo
assigned intervention
1 Was lost to follow-up
15 Withdrew

15 Were excluded
4 Did not undergo
assigned intervention
2 Were lost to follow-up
9 Withdrew

297 Were included in the efficacy analysis
287 Were included in analyses
of biopsies performed and
treated rejection episodes
153 and 148 Were included in analyses
of patient satisfaction and
quality of life at 1 yr,
respectively

305 Were included in the efficacy analysis
292 Were included in analyses
of biopsies performed and
treated rejection episodes
155 and 146 Were included in analyses
of patient satisfaction and
quality of life at 1 yr,
respectively

Figure 1. Screening, Randomization, and Inclusion in Analyses.
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profiling group (P = 0.01) (Table 1). The interval
between transplantation and randomization was
6 through 12 months in the case of 15% of the
patients, 13 through 36 months in the case of 68%,
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and 37 through 60 months in the case of 17%.
The median duration of follow-up after randomization was 19.0 months (interquartile range, 9.6
to 23.8).

Table 1. Baseline Characteristics of the Study Population.*
Gene Profiling
(N = 297)

Biopsy
(N = 305)

P Value

Mean

53.9±12.9

54.3±12.8

0.68

Range

18.0–74.0

19.0–78.0

244 (82.2)

249 (81.6)

Characteristic
Age — yr

Male sex — no. (%)

0.92

Race or ethnic group — no. (%)†
236 (79.5)

232 (76.1)

0.33

Hispanic

White

22 (7.4)

17 (5.6)

0.41

Black

25 (8.4)

46 (15.1)

0.01

Asian or Pacific Islander

7 (2.4)

6 (2.0)

0.79

Other

7 (2.4)

4 (1.3)

0.38

Coronary artery disease

127 (42.8)

130 (42.6)

Nonischemic cardiomyopathy

Indication for cardiac transplantation — no. (%)

0.96
152 (51.2)

155 (50.8)

Valvular heart disease

6 (2.0)

5 (1.6)

Congenital heart disease

9 (3.0)

9 (3.0)

Graft vasculopathy or retransplantation

1 (0.3)

3 (1.0)

Other

2 (0.7)

3 (1.0)

Interval between transplantation and randomization
— no. (%)
6–12 mo

43 (14.5)

44 (14.4)

>0.99

13–36 mo

205 (69.0)

208 (68.2)

0.86

37–60 mo

49 (16.5)

53 (17.4)

0.83

Cytomegalovirus status — no. (%)
Donor and recipient positive

128 (43.1)

109 (35.7)

0.07

Donor and recipient negative

44 (14.8)

47 (15.4)

0.91

Donor positive and recipient negative

59 (19.9)

78 (25.6)

0.10

Donor negative and recipient positive

50 (16.8)

58 (19.0)

0.52

Unknown

16 (5.4)

13 (4.3)

58 (19.5)

57 (18.7)

0.84

168 (56.6)

181 (59.3)

0.74

4 (1.3)

5 (1.6)

Antithymocyte globulin

52 (17.5)

53 (17.4)

Basiliximab

30 (10.1)

43 (14.1)

Daclizumab

66 (22.2)

63 (20.7)

Alemtuzumab

12 (4.0)

13 (4.3)

4 (1.3)

4 (1.3)

Use of ventricular assist device before transplantation
— no. (%)
Induction therapy — no. (%)
Any
Muromonab-CD3

Other

1894
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Table 1. (Continued.)
Gene Profiling
(N = 297)

Characteristic

Biopsy
(N = 305)

P Value

Immunosuppressive therapy — no. (%)‡
79 (26.6)

83 (27.2)

0.66

Tacrolimus

Cyclosporine

218 (73.4)

218 (71.5)

0.65

Mycophenolate mofetil or mycophenolic acid

237 (79.8)

250 (82.0)

0.53

26 (8.8)

15 (4.9)

0.08

Azathioprine
Sirolimus
Prednisone

53 (17.8)

65 (21.3)

0.31

132 (44.4)

122 (40.0)

0.28

247 (83.2)

258 (84.6)

0.66

Medical history after transplantation — no. (%)
Hypertension treated with medication
Diabetes mellitus treated with medication

115 (38.7)

114 (37.4)

0.74

Renal insufficiency§

147 (49.5)

157 (51.5)

0.68

Lipid-lowering drug prescribed

275 (92.6)

283 (92.8)

>0.99

38 (12.8)

49 (16.1)

0.30

63.2±6.0

63.4±6.1

0.67

Cancer
Left ventricular ejection fraction at first study visit¶

* Plus–minus values are means ±SD. Data are for the intention-to-treat population.
† Race or ethnic group was self-reported.
‡ This category includes all medications taken by patients while they were enrolled in the study.
§ Renal insufficiency was defined by a serum creatinine level of less than 1.5 mg per deciliter (133 μmol per liter).
¶ Data for first-visit measurements of left ventricular ejection fraction were missing for 9 patients in the gene-profiling
group and 15 in the biopsy group. In the case of five patients in the gene-profiling group and seven in the biopsy
group, the left ventricular ejection fraction could not be calculated at the core echocardiography laboratory owing to the
poor quality of the echocardiogram. In these cases, the measurement of left ventricular ejection fraction that was obtained closest to the first study visit was used in the analysis.

Primary Outcome

The 2-year rate of the composite primary outcome
in the gene-profiling group was similar to the
rate in the biopsy group (14.5% and 15.3%, respectively; P = 0.86) (Fig. 2A). The corresponding
hazard ratio was 1.04 (95% confidence interval
[CI], 0.67 to 1.68), with the upper boundary falling below the prespecified noninferiority margin.
Therefore, monitoring for rejection with geneexpression profiling was noninferior to monitoring with routine biopsies with respect to the prevention of the primary outcome. The results for
the individual components of the primary outcome are shown in Table 2. There was no significant interaction with respect to the primary outcome between the assigned group and either the
interval between transplantation and randomization (≤12 months vs. >12 months) or the transplantation center (P = 0.86 and P = 0.99, respectively). Because there was a higher proportion of
black patients in the biopsy group than in the
gene-profiling group and a higher observed rate

n engl j med 362;20

of the primary outcome among black patients
than among nonblack patients (18.3% vs. 10.2%,
P = 0.07), we performed an additional analysis adjusting for black race in our Cox model. We found
that the results were consistent with those of our
primary analysis (hazard ratio, 1.13; 95% CI, 0.70
to 1.84).
Deaths

The overall rate of survival in our study did not
differ significantly according to the method of
monitoring (Fig. 2B). The 2-year cumulative rate
of death was 6.3% in the gene-profiling group and
5.5% in the biopsy group (P = 0.82) (Table 2). The
adjudicated causes of death (cardiovascular vs. noncardiovascular) were similar in the groups.
Biopsies Performed and Related Complications

A total of 409 biopsies were performed in the
gene-profiling group, as compared with 1249 performed in the biopsy group (Fig. 3, and Table 8 in
the Supplementary Appendix). The frequency of
nejm.org
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No. at Risk
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297
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252

221
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160

137
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273

252

207
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133

130

36

B
100
90

P=0.82 by log-rank test

Patients Surviving (%)
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Geneexpression
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259
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215

176

154
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147

284

284

284

209

177

147

144

144

Figure 2. Kaplan–Meier Estimates of the Time to the Composite Primary
Outcome and the Probability of Survival.
Panel A shows the time to the first occurrence of any of the following primary events: rejection with hemodynamic compromise, graft dysfunction
due to other causes, death, or retransplantation. Only the first event that
was part of the composite primary outcome was considered. Panel B shows
the probability of overall survival. The inset in each panel shows the same
data on an enlarged y axis and on a condensed x axis.
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biopsies was 0.5 biopsies per patient-year of follow-up in the gene-profiling group and 3.0 biopsies per patient-year of follow-up in the biopsy
group (P<0.001). In the gene-profiling group, 67%
of the biopsies were performed because of elevated gene-expression profiling scores; another 17%
were performed, per protocol, when signs, symptoms, or echocardiographic manifestations of graft
dysfunction were present at the time of a clinic
visit, 13% were performed as part of a follow-up
assessment after treatment for rejection, and 3%
were performed outside the study protocol. In 28
instances (9% of the cases in which there were
elevated scores), consistently high gene-expression profiling scores did not result in performance
of a biopsy (see the Methods section). Biopsyrelated complications occurred in four patients
in the biopsy group and in one patient assigned
to the gene-profiling group (Table 2).
Intensity and Complications
of Immunosuppression

The overall intensity of immunosuppression
throughout the study was similar in the geneprofiling group and the biopsy group (see the Supplementary Appendix). Despite a higher number
of infections among patients monitored with geneexpression profiling than among those monitored
with biopsies (53 vs. 43) (Table 7 in the Supplementary Appendix), we found no significant differences between the groups in mean levels of
calcineurin inhibitors (Section 2.2 in the Supplementary Appendix). The mean serum creatinine
levels during the study were also similar in the
two groups (1.42±0.41 mg per deciliter [125.5±
36.2 μmol per liter] in the gene-profiling group
vs. 1.42±0.59 mg per deciliter [125.5±52.2 μmol
per liter] in the biopsy group, P = 0.95). Finally, the
incidence of any cancer was similar in the two
groups (3.7% in the gene-profiling group and 3.3%
in the biopsy group, P = 0.83).
Rejection Episodes

A total of 34 treated episodes of rejection occurred
in the gene-profiling group, as compared with 47
episodes in the biopsy group (Section 2.4 and Table 9 in the Supplementary Appendix). In the geneprofiling group, six treated episodes of rejection
were initially detected as a result of a biopsy performed because of an elevated gene-expression
score. In the biopsy group, 22 treated episodes of
rejection were asymptomatic and were detected
on routine biopsy alone.
nejm.org
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Table 2. Trial Outcomes.
Outcome

Total Events
Gene Profiling

2-Yr Cumulative Event Rate

Biopsy

Gene Profiling

P
Value

Hazard Ratio
(95% CI)*

Biopsy

%
Composite primary outcome — no. of events†

34‡

33

11

13

Cellular, biopsy-confirmed‖

2

7

Antibody-mediated, biopsy-confirmed**

3

1

Mixed, biopsy-confirmed

3

2

Probable, not biopsy-confirmed††

4

3

11

14

1

1

11

13

11

6

Cardiovascular

7

5

Noncardiovascular or unknown

4

1

13

12

Cardiovascular

8

9

Noncardiovascular or unknown

5

3

Adverse events associated with biopsy —
no. of patients/total no. (%)§§

1/287 (0.3)

4/292 (1.4)

Tricuspid-valve incompetence¶¶

0/287

2/292

Symptomatic pericardial effusion‖‖

0/287

1/292

Bleeding

0/287

1/292

Other***

1/287

0/292

Rejection with hemodynamic compromise
as first event — no. of events

Graft dysfunction due to other causes as first
event — no. of events
Allograft vasculopathy
Nonspecific graft failure
Death as first event — no.

Death at any time — no. of events‡‡

14.5

15.3

0.86§

1.04 (0.67–1.68)

>0.99¶

0.68¶

0.23¶

6.3

5.5

0.82§

1.10 (0.50–2.40)

*
†

The hazard ratio was estimated with the use of the Cox model, which included study-group assignment as a factor.
The composite primary outcome was rejection with hemodynamic compromise, graft dysfunction due to other causes, death, or retransplantation. The analysis was performed on the basis of the first occurrence of any of the components. One patient in the biopsy group
underwent retransplantation. The event was categorized as a death in the analyses, as specified by the statistical-analysis plan.
‡ One case of graft dysfunction was adjudicated as due to probable rejection (not biopsy-confirmed), allograft vasculopathy, or both.
Therefore, this event is listed twice, once in the category of probable rejection and once in the category of allograft vasculopathy.
§ P values were calculated with the use of the log-rank test.
¶ P values were calculated with the use of Fisher’s exact test for categorical variables.
‖ Confirmation of cellular rejection on biopsy required that a local pathologist classify the biopsy specimen, according to the International
Society for Heart and Lung Transplantation system for grading rejection, as a grade of 2R (according to the 2004 version, in which the
grades range from 0 to 3R) or 3A (according to the 1990 version, in which grades range from 0 to 4). Higher numbers indicate more severe rejection.
** Confirmation of antibody-mediated rejection on biopsy required histologic evidence of acute capillary injury or immunopathological evidence of antibody-mediated injury (as assessed with the use of immunofluorescence or immunohistochemical testing).
†† Probable rejection included events that, in the absence of histologic confirmation on biopsy, were considered by the end-points committee to be caused by rejection.
‡‡ This category includes deaths that occurred as the first event, as well as deaths that occurred after a nonfatal primary event.
§§ The total number includes all patients who completed at least one study visit and who were followed for a minimum of 30 days in the
study.
¶¶ This category included tricuspid regurgitation with a grade of moderate-to-severe or higher on the basis of the local echocardiography report. One patient had severe tricuspid regurgitation, and the other patient had moderate-to-severe tricuspid regurgitation.
‖‖ Hypotension and presyncope developed in one patient in the biopsy group after a routine heart biopsy; an echocardiogram in this patient
showed a new, moderate-grade pericardial effusion that required hospitalization for observation. The effusion resolved without the need
for drainage.
*** One patient was inadvertently given subcutaneous formalin instead of lidocaine before venous cannulation, and the wound required local
débridement by a plastic surgeon.
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Figure 3. Frequency of Endomyocardial Biopsies Performed.
The distribution of outpatient endomyocardial biopsies performed per
patient-year of follow-up is shown for patients in the biopsy group and
patients in the gene-profiling group. The majority of patients in the geneprofiling group (88%) underwent two biopsies or fewer per patient-year,
and 50% did not require a biopsy during the study.

Health Status and Patient Satisfaction

At enrollment, no significant differences were
found between the two groups in the physicalhealth and mental-health summary scores of the
SF-12 (Table 10 in the Supplementary Appendix).
The physical-health summary score was higher in
the biopsy group than in the gene-profiling group
at 1 year (47.3 vs. 44.7, P = 0.03), but both the mean
physical-health and mental-health summary scores
were similar in the two groups at 2 years (physical-health score: 45.1 in the gene-profiling group
and 46.2 in the biopsy group, P = 0.52; mentalhealth score: 50.8 and 50.7 in the two groups,
respectively; P = 0.66). At enrollment, the scores
for patient satisfaction were similar in the geneprofiling group and the biopsy group (6.86 and
6.74, respectively; P = 0.61). During the course of
the study, there was an increase in the satisfaction score in the gene-profiling group, to 8.15 in
year 1 and 8.74 in year 2, whereas the scores in
the biopsy group remained similar throughout
the study to the score at enrollment (6.64 in year
1 and 6.66 in year 2). The differences in patientsatisfaction scores at 1 and 2 years between patients in the gene-profiling group and those in
the biopsy group were significant (P<0.001 for
both comparisons).
1898

n engl j med 362;20

In this multicenter study involving patients who
had received a cardiac transplant more than
6 months before enrollment and whose condition
was clinically stable, the use of gene-expression
profiling of peripheral-blood specimens in combination with clinical and echocardiographic assessment, as compared with the use of endomyocardial biopsies according to standard practice,
resulted in a significant reduction in the number
of biopsies performed and did not result in an
excess of adverse outcomes. In addition, patient
satisfaction was higher with the gene-expression
profiling method of monitoring than with the
biopsy method, reflecting the preference of many
patients for avoiding an invasive procedure.
For gene-expression testing, a score below 34
was used in the majority of cases (97%) to identify patients who were at low risk for rejection
and in whom a biopsy was not needed. Although
the use of a higher threshold may further minimize the number of biopsies needed, the results
of our trial suggest that a score below 34 represents a prudent threshold to use in clinical practice in the case of patients for whom the interval
after transplantation is more than 6 months.
There were fewer treated episodes of rejection
in the gene-profiling group than in the biopsy
group, and this difference was due primarily to
fewer asymptomatic episodes of rejection observed
in the gene-profiling group than in the biopsy
group (see the Supplementary Appendix). Although
gene-expression profiling may not have detected
all the cases of asymptomatic rejection, we did
not observe an excess 2-year cumulative risk of
graft dysfunction, death, or retransplantation in
the gene-profiling group. This observation suggests that not all asymptomatic episodes of rejection that occur more than 6 months after transplantation warrant treatment. Some of these
episodes may be explained by a misreading on
the part of pathologists of benign nodular endocardial infiltrates (Quilty lesions) in biopsy specimens, whereas others may represent a subgroup
of histologically defined rejection episodes that
resolve without augmentation of immunosuppression.19,20 Conversely, undetected rejection may
lead to long-term graft dysfunction through such
mechanisms as progressive myocardial fibrosis
or coronary-artery intimal hyperplasia. The late
consequences of untreated rejection are poorly
understood and may not have been clinically apnejm.org
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parent during the follow-up period (a median of
19 months) in our study.
Only 6 of the 34 treated episodes of rejection
in the gene-profiling group were detected with
the use of the gene-expression test. The other episodes were detected because of the presence of
overt symptoms of heart failure or echocardiographic evidence of graft dysfunction. These observations raise the possibility that clinical observation may detect the majority of serious
rejection episodes. Some transplantation centers
in the United States and many centers worldwide
have discontinued the practice of performing routine biopsies after the first year post-transplantation.21 However, many physicians who treat
transplant recipients have been reluctant to adopt
this practice until the relative safety of such an
approach can be shown in a comparative trial.
Therefore, the majority of transplantation centers
in the United States continue to perform biopsies
beyond the first year post-transplantation, although there is considerable institutional variation in the frequency and duration of monitoring
for rejection.2 There has not been sufficient equipoise to justify a comparison of monitoring by
means of clinical observation with monitoring by
means of routine biopsies, but our findings may
provide the basis for such comparisons in future
studies.
The results of our trial must be interpreted in
the context of several important limitations. Only
patients who had received a cardiac transplant
more than 6 months previously were eligible for
enrollment. Such patients have a lower risk of rejection and may be at lower risk for adverse outcomes due to undetected rejection than patients
for whom the interval after transplantation is
6 months or less. We chose to enroll patients who
were at a lower risk for rejection because the relative safety of an approach that minimizes the
number of biopsies has not been confirmed, and
we did not want to expose the study participants
to an undue risk of adverse events. This decision
reflects the characteristically conservative approach
to the care of cardiac-transplant recipients and
the reluctance of clinicians and patients to accept even a small possibility of causing harm.
Only 20% of potentially eligible patients were
enrolled in the study. Patients who had received
a cardiac transplant less than 3 years previously were recruited preferentially, and a substantial number of eligible patients were not
enrolled, owing to patient or physician prefern engl j med 362;20

ences. Details regarding these patients were not
available, but it is likely that patient selection
was biased toward the inclusion of low-risk patients, thereby restricting the generalizability of
our findings. This limitation should be taken into
account by clinicians when they consider the use
of gene-expression profiling in the care of their
patients.
The low projected event rates and the limited
number of available patients necessitated the
choice of a wide noninferiority margin. The trial’s
reduced power was reflected in a relatively wide
confidence interval that does not exclude the possibility of a 33% decrease in primary event rates
(or 1.8 fewer events per 100 patient-years) or of a
68% increase (3.7 excess events per 100 patientyears) among patients in the gene-profiling group.
Our composite outcome was chosen to include
both clinically overt rejection and the possible
consequences of undiagnosed rejection. Because
graft dysfunction, death, or retransplantation may
be caused by conditions other than rejection, the
inclusion of these end points may have further
reduced the trial’s power. A more robust test of
noninferiority would have necessitated a considerably larger sample than that which was feasible, given the limited number of cardiac transplantations performed worldwide.22
Finally, the lack of blinding in the study may
have influenced the intensity of immunosuppression in the gene-profiling group. However, we did
not observe any significant differences between
the groups in mean levels of calcineurin inhibitors throughout the study, in serum creatinine
levels, or in the incidence of neoplasms.
In conclusion, our study suggests that geneexpression profiling of peripheral-blood specimens
may offer a reasonable alternative to routine biopsies, for monitoring cardiac-transplant recipients for rejection if the interval since transplantation is at least 6 months and the patient is
considered to be at low risk for rejection. However, the study had limited power to allow for a
firm conclusion to be reached regarding the use
of gene-expression profiling as a substitute for
the performance of biopsies. A larger trial with a
narrower noninferiority margin and a longer follow-up period would be necessary to definitively
resolve this issue.
Supported by XDx, maker of the AlloMap test. Stanford University holds equity in XDx.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
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APPENDIX
Members of the IMAGE Study Group are as follows: Steering Committee: H. Valantine (chair), M. Pham (co-chair), A. Anderson, D.
Baran, R. Bogaev, T. Cappola, W. Cotts, M. Deng, G. Ewald, A. Kao, A. Kfoury, R. Starling, J. Teuteberg. Data and Safety Monitoring
Board: R. Bourge (chair), M. Johnson, D. Naftel, S. Pham. Endpoints Committee: B. Edwards, M. Felker, L. Wagoner. Echocardiography
Core Laboratory: D. Liang (director), J. Chow, A. Paloma, J. Puryear, A. Rodriguez (cardiac sonographers). Data Coordinating Center:
G. Alexander, B. Elashoff, T. Klingler, S. Wang, H. Wolters (statisticians), U. Patil, J. Scheel (data management), A. Clark, D. Pieretti,
E. Shocron, N. Sternheim, T. Wolf (clinical operations), H. Baron, J. Yee (clinical sciences).
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